Whilst circulating FGF-23 levels rise rapidly during AKI [14] and a causal role for FGF-23 in the pathogenesis of left ventricular hypertrophy has previously been unveiled, suggesting that chronically elevated FGF-23 levels contribute directly to cardiac mortality in patients with CKD [37]. The gene discussed is FGF23; the disease is left ventricular hypertrophy.